1. Background {#sec1}
=============

Intravenous catheters and those related devices used to gain access to the veins for the purpose of infusing medications or solutions have evolved significantly over the past three decades. One of the more noticeable changes involves the way intravenous devices are accessed. Early concerns over needle safety for healthcare workers led to the creation of products that provide needle-free access. While these products did eliminate the risk of accidental needle injury for the clinician, some needleless products raised new issues for the patient; namely, a noted increase in the occurrence of catheter associated bloodstream infections (CABSI) and central line associated bloodstream infections (CLABSI) \[[@B1]--[@B3]\]. Risk factors for infection include poor adherence to aseptic technique, needleless connector (NC) design variations, and inconsistent health care staff education and training \[[@B1]--[@B3]\]. NC are used on virtually all intravascular devices in the USA; they provide an easy access point for syringe or tubing attachment and have now become the central access point for all connections. Yet, despite providing some level of safety, concerns over infection related to NC contamination exist. Surface design, gaps around valve closure surface, segmented fluid pathway with dead space, differing internal mechanisms, clear or obscured visibility, variable blood reflux, clamping sequences, and different flushing instructions, depending on the type of NC, all play a part in the level of risk associated with the device. Before the advent of NC, clinicians had an intuitive understanding that prior to penetrating the septum with the needle the septum required disinfection. Current surface disinfection of NC is not necessarily intuitive. Initially, needleless split septum access points used a blunt "needle-looking" type cannula. As a result, the disinfection process remained intuitive. Split septum access devices continue to be recommended as a lower risk option for needleless connection; however, they have lost popularity because they require multiple parts and pieces for access and allow direct needle access through the septum/diaphragm leading many facilities to switch to luer access devices. With the changes to the access point using direct luer connection through the NC, the intuitive sense to disinfect the surface prior to access is lost; many clinicians fail to realize the consequences of this breech in aseptic technique \[[@B4]--[@B6]\]. Colonization of catheter hubs and NC, with subsequent bacterial ingress into the catheter lumen, is considered the cause of 50% of postinsertion catheter-related infections \[[@B3]--[@B7]\]. Disinfection of the exposed surface of the NC is necessary to avoid contamination and subsequent intraluminal biofilm formation and protect patients from infection.

Vast improvements have been made in the reduction of CLABSIs attributed to insertion procedures. The results of the groundbreaking Keystone initiative demonstrated the effect of five measures, known as the Central Line Bundle, on the improvement of outcomes during insertion of central venous catheters \[[@B9], [@B8]\]. Consistent application of the bundle, with compliance verified during the insertion procedure (checklist), has reduced insertion related CLABSI by more than 44% in the USA \[[@B10]\]. However, despite the successes of the insertion bundle, full compliance more than seven years later is still lacking, with reported compliance rates at one institution ranging from 0.0% at the beginning of the intervention to 37.1% (139/375), according to the Jeong study, with similar results in other institutions \[[@B12], [@B14], [@B11], [@B13]\]. Even in institution where full compliance of the bundle exists, CLABSIs are still occurring \[[@B18]\]. Disinfection of the NC access site was not included in the insertion related central line bundle. The goal of any effective infection prevention program is zero CLABSIs. To reach the goal of zero, consideration must be given for the pathogenesis of catheter related infections and an investigation into current human factors of catheter management preventing achievement of this goal.

While many experts agree that application of the insertion bundle is one of the best ways to prevent insertion-related infection, the bundle does not address NC, aseptic access, or any postinsertion catheter usage issues. A Pennsylvania study reported that 71.7% (468/653) of central line infections occurred five days or more after insertion and may have been directly related to use and care of intravascular devices \[[@B16], [@B18]--[@B17]\]. Contamination of the catheter directly through the catheter hub has been confirmed through published studies \[[@B19], [@B23], [@B20]--[@B22]\]. These studies found that bacteria identified on external hub surfaces were also present in biofilm sampled from random locations within the needless connector. Research performed at one institution revealed that patient skin flora was not the source of catheter related bloodstream infections in any of their cases; all infections in this study originated from the catheter hub \[[@B6], [@B22]\]. Infections later in the life of the catheter develop from improper catheter manipulation, failure to perform hand hygiene, inadequate time to clean NC, inadequate training, and poor access and exit site management \[[@B2], [@B24], [@B17], [@B21]\]. Disinfection of a catheter hub prior to flushing or prior to the administration of medications is required for all aseptic access, yet in the Karchmer study, 31% of clinicians did not even attempt to disinfect, even when under active observation \[[@B1], [@B9], [@B25], [@B26]\]. In a study by Lee the disinfection compliance by clinicians prior to NC access was measured at only 10% \[[@B27]\]. This common break in aseptic technique sets the stage for biofilm formation within NC and catheters and increases the potential for delayed infection of both central and peripheral catheters \[[@B28], [@B16], [@B30], [@B21], [@B29]\]. The results of the Pennsylvania Patient Safety Advisory Report and independent biofilm sampling of NC suggest that more attention is needed for aseptic access and maintenance practices \[[@B15]\].

2. What Is Disinfection? {#sec2}
========================

According to the Epic3 Evidence-Based Guidelines for Preventing Healthcare Infections, disinfection is defined as the use of chemical or physical methods to reduce the number of pathogenic microorganisms on surfaces to a level at which they are not able to cause harm, but which does not usually destroy spores \[[@B31]\]. These guidelines further state that disinfection methods used in combination with cleaning blood or other debris off the surface as disinfectants have limited ability to penetrate organic material \[[@B33]\]. The Association for Professionals in Infection Control (APIC) defines disinfection as a process to eliminate microorganisms accomplished with the use of liquid chemicals or pasteurizing; process works best by having proper contact time and dilution of disinfection agent \[[@B32]\]. Recommendations from the Centers for Disease Control \[[@B33]\], the Agency for Healthcare Research and Quality \[[@B34]\], the Society for Healthcare Epidemiology of America \[[@B35]\], and the Infusion Nurses Society \[[@B37], [@B36]\] state that NC should be consistently and thoroughly disinfected using mechanical friction with 70% alcohol, alcoholic chlorhexidine, or povidone iodine prior to each access of an intravascular device and listed in evidence as a Category 1A.

2.1. Goal {#sec2.1}
---------

The goal of this review is to assess current literature related to disinfection of NC to establish recommendations that promote aseptic access, reducing infection risk for the patient.

2.2. Search Methodology {#sec2.2}
-----------------------

The purpose of this systematic review was to evaluate the supporting evidence for disinfection practices of NC, catheter hub, stopcock, and side ports that reduce the transfer of microorganisms through intravascular device access. This report is based on an electronic systematic literature search and review of published materials from Pubmed, Medline, Scopus, Ovid, jStor, CINAHL, Cochrane, Athens, and ScienceDirect by cross-referencing these key terms for years 1977--December 2014. High level evidence from RCTs that tested "cause and effect" relationships between different disinfection approaches for NC and patient infection was initially sought. Since no RCTs were found, lower level evidence including clinical and in vitro (laboratory) studies was reviewed, as long as these included reporting of quantitative data. Broad MeSH search term "disinfection" and "needleless connector" combinations were used with additional keywords listed below:disinfection, antiseptic, alcohol, chlorhexidine, and anti-infective agents,intravenous, intravascular, and vascular access,hub, catheter hub, scrub the hub,intravenous connector, NC, luer activated device, and mechanical valve,aseptic practices, contamination, and compliance,education, staff education, and medical education,infection, infection prevention, catheter related infections, CLABSI, bloodstream infections, bacteremia, sepsis, and cross-infection,catheter maintenance and line care,insertion and bundle,intravenous technology,catheter cap, access port, disinfecting cap, antimicrobial cap, hub protection cap, and port protector,Infection prevention guidelines and recommendations.

Additional studies were cross-referenced through manual search. Conference posters and abstracts were included in the review. Manufacturers websites of disinfection ports and two manufacturers (Excelsior Medical, Neptune, NJ; Ivera Medical Corporation, San Diego, CA) were contacted directly requesting all published materials and posters on disinfection products. There were no identified formal published systematic reviews of the effectiveness of NC disinfection practices, indicating a knowledge gap in this area. Search results were evaluated by title, abstract, and content. Selected papers were subjected to full-text assessment. Initial selection process and critique was performed by one researcher (NM), with evidence rating performed by two researchers independently (NM and JF), with any disagreement in quality rating resolved by discussion.

2.3. Inclusion/Exclusion Criteria {#sec2.3}
---------------------------------

Criteria checklist for inclusion was any NC disinfection publications and abstracts that fit subcategories for disinfection, hub contamination/infection prevention, education/compliance, surveys, and guidelines/recommendations for disinfection. Inclusion criteria consisted of publications meeting search terms and topic requirements under sub groupings:disinfection agents used on intravascular device surfaces including studies and reviews of NC and infection prevention,sources of contamination through intravascular devices,education and compliance for infection prevention,guidelines and recommendations for infection prevention with disinfection.

Exclusion criteria werenonresearch papers,studies of adult, pediatric, or neonatal increasingly important role patients not inclusive of intravascular device disinfection practices,primary populations outside acute care,publications not translated into English,studies prior to 1984.

3. Results {#sec3}
==========

The systematic review of these topics yielded a total of 433 papers and abstracts. After initial review 259 articles did not meet eligibility requirements and were removed. Included studies consisted of 140 publications dealing with disinfection/catheter hub/NC contamination with 34 abstracts/posters. Of the studies 67 were graded according to the strength of the study. The study results and ratings of the literature are included in Tables [1](#tab1){ref-type="table"}--[5](#tab5){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}, with recommendations are represented in [Table 6](#tab6){ref-type="table"}.

3.1. Why Disinfect? {#sec3.1}
-------------------

A catheter is inserted into a vein or artery to provide a pathway for the administration of medications or solutions necessary to improve a patient\'s health or condition. Because catheters provide an open conduit into the vasculature, a NC is attached, via luer threaded connection, to the integrated hub end of the catheter establishing a closed system. Studies reflecting benefits of closed systems with NC have trended toward demonstration of protection for catheter and hub colonization \[[@B4], [@B38]\]. In a prospective controlled study by Rosenthal and Maki and multicenter prospective cohort by Rangel-Frausto et al., open systems compared to closed systems resulted in major reductions in catheter related infections \[[@B39]\]. NC used as a closed system must be weighed with consideration for potential negative factors of design features, poor aseptic practices, and lack of disinfection that all contribute to risk of infection \[[@B2], [@B40], [@B41]\].

Any puncture through the protective skin barrier creates a portal for bacteria to enter the body. Recognized routes of catheter contamination are classified as either extraluminal or intraluminal and include (a) migration of microorganisms from the skin at the insertion site (considered the source in short term infections), (b) catheter hub contamination, (c) hematogenous seeding from another infection source in the body, and (d) direct contamination from an infusate \[[@B33], [@B18], [@B42]\]. After insertion of a catheter, introduction of microorganisms occurs primarily from two routes: the skin/insertion track or through the lumen of the catheter \[[@B47], [@B43]--[@B46]\]. The greatest risk for contamination of the catheter after insertion is the access hub with 33--45% (402/900) contaminated in normal patient use \[[@B6], [@B47], [@B48]--[@B52]\]. In early studies by Sitges-Serra colonization of the catheter hub was considered the primary pathogenesis of catheter associated infection \[[@B47], [@B22]\]. Linares and colleagues reported 14 episodes of sepsis (70% of total catheter related septic events) resulted from hub-related contamination \[[@B46], [@B53]\]. Moro reported hub colonization in only 3.5% (21/607), but found that this group was responsible for severe systemic infections more frequently \[[@B48]\]. Studies indicate that, during periods of nonuse, colony forming units (CFU) are present on access hubs in numbers ranging from 15 to 1000 CFU, representing quantities sufficient to cause contamination, biofilm formation, and potentially bacteremia if not sufficiently disinfected prior to access \[[@B3], [@B5], [@B19], [@B64], [@B17], [@B20], [@B54]--[@B63]\]. As demonstrated by multiple studies, infections are drastically lower or eliminated by disinfecting or covering the access hub with an antimicrobial cap \[[@B28], [@B66]--[@B72], [@B22], [@B46], [@B65]--[@B69]\]. Hub contamination plays an increasingly important role with infection risk the longer the catheter is in place \[[@B47]\]. Intraluminal contamination and subsequent colonization become more prominent with longer dwell times \[[@B17], [@B73]\]. Perez and associates found 59% (42/75) of one group of NC colonized with biofilm and Salzman found that 71% (20/28) of catheter related infections originated in the catheter hub presumably from contamination \[[@B47], [@B75], [@B76], [@B74]\]. Clearly hub contamination is a causative element in catheter related infections and one that demonstrates the necessity for effective hub disinfection prior to access \[[@B17], [@B22], [@B46], [@B53], [@B65], [@B77]\].

3.2. What to Disinfect? {#sec3.2}
-----------------------

Disinfection points to gain access to intravenous or intravascular devices may include tubing side ports, direct catheter connections, stopcocks with needle free caps, NC of various types (split septum, mechanical valves, positive pressure valves, zero, or neutral connectors), traditional silicone septum, or other forms of access integrated with the catheter or tubing. Any intravascular access point with a surface open to the environment requires disinfection prior to use, as it acts as the immediate portal of entry for intraluminal contaminants \[[@B79], [@B64], [@B22], [@B46], [@B53], [@B65], [@B78]--[@B81]\]. Needle free devices constitute more than 80% of access devices, are recommended by Centers for Disease Control for all tubing/catheter access, and are now more common than traditional covered septal access ports which allowed needles to pass easily through the silicone or rubber covered access \[[@B33], [@B82]\]. Primary areas of focus for disinfection of access sites are the point where the sterile syringe or tubing contacts the site, as in the top septum surface, and the threads or side surfaces \[[@B7], [@B63], [@B83]\]. Manufacturers are required to include instructions for device use and disinfection recommendations with each product to guide in the correct and safe usage of the NC.

Effective disinfection of a NC is influenced by several factors including: ability to clean the NC surface, the amount and position of grooves or gaps present, and the roughness or smoothness of the septum \[[@B1], [@B3], [@B7], [@B85], [@B78], [@B83]--[@B86]\]. All NC consist of a septum, a fluid pathway and a mechanism for activation; the design, space, volume, and human factors all affect how easy a product is to use and disinfect, and may also act as contributors to the potential risk of catheter associated bloodstream infection \[[@B3], [@B85], [@B78], [@B84], [@B87], [@B88]\]. NC have gaps of differing widths between the septal seal and the housing which may allow ingress of microorganisms \[[@B7], [@B79], [@B64], [@B63]\]. Adequate cleaning or need for additional cleaning of the septal access site may be based on the specific design features of the individual NC \[[@B2], [@B4], [@B5], [@B7], [@B91], [@B20], [@B49], [@B82], [@B89]--[@B92]\]. New products or technology should be transitioned into a healthcare facility only after a complete evaluation of both the research and the performance of the product to determine the impact of the change on patient outcomes \[[@B93], [@B97], [@B100], [@B77], [@B90], [@B94]--[@B99]\].

3.3. Disinfection Practices {#sec3.3}
---------------------------

Recommendations from both the Centers for Disease Control and the Infusion Nurses Society state clinician should minimize contamination risk by disinfection the access ports of the add-on device using friction with an appropriate disinfectant (70% alcohol, chlorhexidine, povidone iodine, and iodophors) prior to any access \[[@B33], [@B37], [@B103], [@B101], [@B102]\]. The 70% isopropyl alcohol wipe is most commonly used to disinfect the access surface of NC and has been proven effective or ineffective at disinfection times from 5 seconds to 60 seconds \[[@B28], [@B71], [@B103]--[@B115], [@B51], [@B80], [@B104]--[@B113]\]. The major biocide effect of alcohol occurs while wet and immediately after drying, allowing for dehydration of bacterial cells, whereas alcoholic chlorhexidine is most effective during the drying process, where it enters the cell to cause destruction providing ongoing antimicrobial effect \[[@B78], [@B108]\]. The disinfecting action of chlorhexidine in combination with alcohol, allowing for both immediate and sustained action; has proven to be more effective than either agent alone \[[@B75], [@B51], [@B102], [@B108], [@B112], [@B116]--[@B118]\]. Faster drying time with alcohol makes it superior to other disinfection agents and provides an advantage to chlorhexidine when used in combination. Effectiveness of 70% alcohol disinfection is variable based on application techniques and characteristics of NC surface and design, leading some researchers to conclude that complete disinfection of microorganisms on some NC surfaces may not be achievable \[[@B19]\]. In the Menyhay prospective in vitro study, 20 (67%) of 30 NC disinfected with 70% alcohol resulted in transmission of contaminants (442--25,000 CFU) yet 60 tested with barrier caps (containing 2% chlorhexidine and 70% alcohol) showed only one (1.6%) with transmission of contaminants \[[@B71]\]. In both the Kaler laboratory and the Ruschman randomized experimental design studies, using a 15 second and 60 second scrub respectively, disinfection with 70% alcohol eliminated all microorganisms \[[@B109], [@B119]\]. Kaler performed laboratory testing on contaminated NC with a small sample using 70% alcohol and alcoholic chlorhexidine and found both to be effective for hub disinfection \[[@B119]\]. Two additional studies gave conflicting results. Rupp demonstrated 5 second alcohol disinfection was effective; this was in direct contrast with the Smith study where contact time of 10/12/15 seconds was deemed adequate, but 5 and 8 seconds were not as effective to prevent bacterial transfer \[[@B106], [@B107]\]. Simmons and colleagues found 3/10/15 seconds significantly decreased the bacterial load in an in vitro laboratory study, with some level of bacteria remaining during all duration levels tested; disinfection failed to completely eliminate contaminants \[[@B23]\]. More studies are needed to provide efficacy for optimal time necessary to eliminate surface contaminants.

Research of Macias and associates with 2% chlorhexidine in 70% isopropyl alcohol on skin proved an added substantive effect, even against freshly introduced organisms, for up to 24 hours, establishing this agent as a superior disinfecting agent when longer action is needed, in comparison with single agents of 70% isopropyl alcohol, 10% povidone iodine and 10% sodium hypochlorite \[[@B108]\]. Alcoholic chlorhexidine performed consistently well or better than other disinfection agents in multiple studies \[[@B75], [@B103], [@B51], [@B102], [@B108], [@B117], [@B120]\]. In the research by Hong et al., a 5 second scrub with alcoholic chlorhexidine fully disinfected NC surfaces treated with Pseudomonas Aeruginosa \[[@B117]\]. In the most recent Epic3 United Kingdom report of evidence-based guidelines, recommendations by expert consensus include a 15 second cleansing with alcoholic chlorhexidine prior to and after each access \[[@B31]\]. In actual practice disinfection prior to access is expected, while cleansing after each access is rarely done.

3.4. Passive Disinfection {#sec3.4}
-------------------------

Disinfection research includes various forms of passive antimicrobial hub protection with 70% alcohol caps (SwabCap, Excelsior Medical, Neptune, NJ; Curos Port Protector, Ivera Medical, San Diego, CA;, EffectIV-Cap, Hospira, Lake Forest, IL; DualCap, Catheter Connections, Salt Lake City, UT), iodinated alcohol hub, povidone iodine gauze and specialty covers, and combination chlorhexidine/alcohol caps \[[@B19], [@B28], [@B70], [@B71], [@B79], [@B105]--[@B142], [@B69], [@B116], [@B124]--[@B146]\]. In a randomized prospective trial by Pittiruti, 46 catheters received a 70% alcohol port protector with no detected CLABSIs over 707 catheter days, colonization in two catheters and no contaminated blood cultures \[[@B70]\]. Of note the Pittiruti study resulted in reductions of CLABSIs in the port protector/disinfection cap group and the control group, with improvements attributed to both the disinfection caps and educational efforts. These disinfection caps applied and left in place provide active mechanical friction along with longer contact time creating a physical and chemical barrier between the lumen and the environment \[[@B114]\]. As a progressive CLABSI intervention Posa at St. Joseph Mercy Health System implemented an insertion bundle, chlorhexidine bathing, a maintenance bundle, chlorhexidine dressing for central catheters, and educational programs, however it was not until implementing the 70% alcohol disinfection cap that their rates of CLABSI fell to zero and remained from 2011 to the end of 2012 The disinfection cap placed on all access ports eliminates human factor issues requiring clinicians to remember to carry the necessary disinfection supplies to the bedside or even to remember to perform the act of disinfection before each access \[[@B136]\]. An in vivo hospital study by DeVries gave nurses a choice to use either this single use cleansing cap or a disinfection cap to leave on the NC access site, clinicians preferred the longer lasting disinfection cap \[[@B28]\]. In another retrospective study, Schears noted a predisinfection cap CLABSI rate of 1.682/1000 catheter days and a CLABSI rate of 0.6461/1000 catheter days after implementing disinfection caps, representing a statistically significant 61% reduction in CLABSI \[[@B128]\]. In Wright et al.\'s study at NorthShore University HealthSystem, a four University Hospital system, the intervention with 70% alcohol disinfection caps reported CLABSI rates declining from 1.42/1000 catheter days (16/11,540) to 0.69 (13/18,972) with a 95% confidence interval, based on 799 enrolled patients, representing a statistically significant decrease \[[@B114]\]. Another alcoholic hub protector study by Sweet et al. included 472 patients and 3005 catheter days and showed a decrease in overall CLABSIs from 2.3 to 0.3/1000 catheter days and a PICC CLABSI reduction from 2.3 to 0, a statistically significant change, with an 85.2% compliance rate \[[@B125]\]. Stango and associates reported a 50% reduction in CLABSIs and a savings of \$464,440 per year after alcoholic cap implementation \[[@B126]\]. Numerous studies have demonstrated consistent clinical effectiveness of 70% alcohol caps alone in studies and abstracts graded C or D \[[@B70], [@B114], [@B115], [@B125], [@B129], [@B140], [@B142], [@B116], [@B143], [@B145]--[@B149]\]. Alcoholic chlorhexidine caps are also effective in preventing contamination and completely disinfecting NC access surfaces (combination of alcoholic chlorhexidine in cap form is not commercially available in the USA) \[[@B2], [@B19], [@B71], [@B116], [@B117]\].

Another engineered solution for hub cleaning involves a 70% alcohol foam cap (Site Scrub, Bard Access, Salt Lake City, UT) designed for use as an access site cleansing cap for single use, then discarded. The Holroyd in vitro study at University of Florida compared the single use of this cleansing cap with 70% alcohol to traditional 70% alcohol wipes \[[@B80]\]. When the cleansing cap was used on stopcocks Holroyd found contamination and increased CFU. This study found 70% alcohol wipes and this alcohol cleansing cap were both effective on the surface of NC and catheter hubs \[[@B80]\]. Other groups also used this single use cleansing cap in combination with other 70% alcohol disinfecting caps designed to be left in place until the next access \[[@B28], [@B113]\].

3.5. Clinical Implications {#sec3.5}
--------------------------

Since the advent of NC as access hubs for the administration of medications or fluids, there has been a need to verify compliance with disinfection practices prior to access. During the period of needle usage for catheter access, nurses and doctors intuitively knew the necessity of disinfecting the access septum prior to inserting a needle. With NC, these questions arise: is disinfection always performed prior to access? Is disinfection performed in an effective manner? Do clinicians fully understand the consequences of not performing disinfection? Disinfection practices with alcohol or alcoholic chlorhexidine that include adequate contact disinfection time are effective if performed at all. According to a recent publication by Ryder, an issue was raised regarding whether failure to disinfect is considered a medical error and if so, is this omission considered negligence? \[[@B150]\] Catheter associated infections are a significant safety issue, and contamination caused by lack of aseptic technique is preventable. Once contamination occurs, bacteria attach to the inner lumen of the catheter, begin to grow and form biofilm, making successful eradication extremely difficult \[[@B6], [@B121]--[@B123], [@B22], [@B46], [@B53], [@B60]--[@B62], [@B65], [@B151]\]. Joint Commission now requires hospitals in the USA to protect patients by having a standard and measurable protocol for hub/access site disinfection \[[@B152], [@B153], [@B154]\]. Measurement of compliance with hub disinfection is challenging, requiring direct observation of the action unless disinfection caps/ports are used on all NC hubs as a form of verification. Passive disinfection through hub protectors/disinfection caps have differing designs and colors, leading to easy recognition and validation of compliance with usage. Reimbursement structures in the USA that now promote pay for performance and penalize poor outcomes will assist in driving these passive safety strategies that aid in monitoring and improving compliance with disinfection.

3.6. Issues of Compliance and Monitoring {#sec3.6}
----------------------------------------

While policies for disinfection of access devices are a first step, methods to validate actual practice and patient safety must be integrated into hospital culture. The central line bundle checklist is used as evidence to demonstrate compliance with safety practices during insertion, but the aspect of day to day management is not addressed in the bundle. Care and management of catheters takes up more than 99% of the dwell time of a catheter compared to the one hour or less for catheter insertion. Compliance with aseptic practice is important for both insertion and daily usage. Consistent hand hygiene and gloving performed prior to any procedure or even touching of a catheter helps reduce bacterial transfer. Application of alcoholic chlorhexidine to disinfect skin for central line insertions and now, more and more with peripheral catheter insertions, is helping to reduce bacterial ingress to the bloodstream. Maximum sterile barriers also reduce contamination during the insertion process so that overall, CLABSI rates occurring in the first few days of insertion continue to fall.

Even with the success of the Central Line Bundle on CLABSI reductions, a majority of hospitals remain well above zero for infections. Access and maintenance activities with the catheters may be to blame. When CLABSIs occur well after the 96 hour mark, contamination of the catheter through the NC is likely the culprit. From the evidence presented, NC and catheter hubs are a primary source of bacterial contamination, and subsequent transmission of contamination into the catheter lumen \[[@B6], [@B123], [@B22], [@B46], [@B53], [@B62], [@B65]\]. Just one omission of scrubbing the hub prior to access permits bacterial entry, attachment and biofilm formation that allow the bacteria to strengthen prior to release into the bloodstream. Preventing this form of contamination requires teaching and constant reinforcement of the required practice of regular and consistent disinfection prior to every access. Verification of compliance with hub disinfection by clinicians requires direct observation of the action unless disinfection hub protectors are used, providing a form of passive immediate visual verification. More and more studies are demonstrating lack of compliance with hub disinfection despite educational initiatives and better disinfection agents. Disinfection methods that incorporate prolonged duration of contact with an antiseptic agent to significantly decrease the level of surface bacteria present may provide a solution to the problem of hub contamination and variation in NC designs.

Various studies provide statements regarding conformity or lack of conformity concerning disinfection practices, attributing noncompliance to a lack of universal protocols, excessive workloads (e.g., when clinicians become busy, they are less likely to comply), or just forgetting to bring alcohol wipes to the bedside \[[@B160], [@B9], [@B161], [@B155]--[@B159], [@B138]\]. The Smith study on behavioral intention indicated a negative correlation between performing optimal disinfection with increasing age of clinicians and more years of experience \[[@B157]\]. Clearly there are human factors working against disinfection of hubs prior to access requiring engineered solutions such as passive disinfecting cap strips hanging on intravenous pump poles, supply dispensers of alcohol wipes at the bedside, or on the intravenous pump to ensure greater, even 100% compliance with disinfection each and every time \[[@B157], [@B106]\]. Monitoring and validation of hub disinfection compliance is necessary to determine if other measures are needed such as disinfection caps/port protectors. In an evaluation of 5877 physicians, nurses and technicians, Jardim et al. documented compliance with hub disinfection 38.7% of the time, leaving more than 61% of accesses without disinfection, leading to possible contamination and biofilm growth \[[@B158]\]. Platace et al. evaluated clinician hands during invasive procedures demonstrating 100% of the 48 nurses sampled exceeded acceptable levels of microorganisms, with the potential to contaminate and cause bloodstream infection \[[@B156]\]. Studies show there is a need for clear recommendations and practices that prevent transmission of contaminants through NC \[[@B30], [@B156]\]. Targeting of education for providers responsible for CVAD insertion and care for identifying appropriate indications, performing insertion with the central line bundle, performing surveillance of CLABSI and scrubbing the hub with an appropriate antiseptic are Category IA recommendations by AHRQ as critical components of a comprehensive CLABSI prevention program \[[@B34]\].

3.7. Risk of Bias and Limitations {#sec3.7}
---------------------------------

This systematic review highlights the lack of available high quality research in this area that tests the cause and effect relationship between NC disinfection practices and patient infection outcomes. It also asks the question "What are we basing our clinical practice guidelines on for disinfection of NC?" Absence of high quality RCT evidence required authors to include any clinical observational and cohort studies and laboratory studies. Overall, the evidence base for the effectiveness of various disinfection strategies is low level, resulting in recommendations compiled from the available publications. The strength of this review is that it includes all relevant, currently available pieces of evidence; however there remains a high level of uncertainty in the estimates of effectiveness of various decontamination techniques, and these are highly likely to change with the publication of new studies in the literature. Studies to date have a risk of unintentional bias due to the lack of randomization and control groups/strategies, in addition to small sample sizes and retrospective study designs. Randomized controlled studies are needed to rigorously evaluate the efficacy of disinfection practices and antiseptic hub protectors in preventing patient infection.

3.8. Research Priorities {#sec3.8}
------------------------

Adequately large randomized controlled trials are urgently needed to establish high quality evidence of the efficacy of various disinfection practices to prevent infection. Randomized controlled trials are needed to identify if risk reduction differs with the type of antiseptic, for example, 70% alcohol versus 70% alcohol and chlorhexidine, or with differing concentrations of chlorhexidine in their efficacy for disinfection NC. Research may also validate the substantive effect of alcoholic chlorhexidine on NC and its continued antimicrobial activity on these surfaces, potentially establishing a reduced cleaning frequency or duration for NC. Study considerations for passive disinfection coupled with prefilled flush syringes could demonstrate drastic reduction of hub contamination and intraluminal biofilm colonization, but ultimately patient infection outcomes are needed. Research that replicates solid studies provides a stronger foundation for evidence-based practice and should be encouraged. Translational research is growing, providing clinical implications that directly apply to bedside practices \[[@B28], [@B172]--[@B174], [@B24], [@B91], [@B176]--[@B178]\]. NC disinfection is an excellent subject for efficacy studies utilizing comparative research for various disinfection approaches identifying relative reductions in patient infection risk. Claire Rickard, Ph.D., Professor of Nursing with Griffith University, states it well "We are belatedly realising that to eliminate these complications (infections) we must conduct research, implement evidence-based interventions and reduce the clinical practice variations that lead to their occurrence" \[[@B197]\]. Research and study are necessary as an integral part of professional practice, providing a means to direct clinical activity and to share with rising young clinicians long after we are gone.

4. Conclusion {#sec4}
=============

Aseptic technique is the foundation for safe delivery of intravenous medications and solutions. More and more studies reveal lack of compliance with disinfection of access ports prior to and after access, despite educational initiatives, and better disinfection agents \[[@B1], [@B114], [@B115], [@B134], [@B160], [@B172], [@B9], [@B24], [@B85], [@B161], [@B177], [@B181], [@B186], [@B25]--[@B159], [@B138], [@B198]--[@B205]\]. Rather than creating devices such as the ultraviolet C port to eradicate contamination within the hub, the goal should be to eliminate surface pathogens before entering the NC or catheter. Passive disinfection caps reduce guess work, provide clinicians with a point of use solution, and reduce contamination. It is critical for healthcare facilities and clinicians to take responsibility for compliance with aseptic technique for NC disinfection, to monitor compliance regularly, to involve frontline staff in solutions, and to facilitate education that promotes understanding of the consequences of failure to comply with the standard of care for access site disinfection.
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      Recommendations for disinfecting practices                                                                                                                                                                                                                                                                                                                     Levels of evidence^\*^
  --- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------
  1   Use disinfection on surfaces of needleless connectors, stopcocks and other intravascular access ports immediately prior to any connection, infusion or aspiration with appropriate antiseptic agent (e.g., alcoholic chlorhexidine, povidone iodine, an iodophor, or 70% alcohol). Access catheter connections with sterile devices only \[[@B33]--[@B37]\].   B
                                                                                                                                                                                                                                                                                                                                                                     
  2   Antimicrobial caps/port protectors may be effectively used for passive continuous hub disinfection on needleless connections in accordance with manufacturer instructions, in conjunction with frictional antiseptic wiping between applications and access \[[@B2], [@B6], [@B35], [@B19]--[@B169]\].                                                         B-C
                                                                                                                                                                                                                                                                                                                                                                     
  3   Ensure compliance with hand hygiene, gloving and aseptic practices prior to any contact with intravenous devices and add-on equipment \[[@B6], [@B33], [@B35], [@B123], [@B10]--[@B174]\].                                                                                                                                                                     B
                                                                                                                                                                                                                                                                                                                                                                     
  4   Establish and educate all clinical staff on a standard protocol to disinfect catheter hubs, needleless connectors and ports prior to and after each access \[[@B37], [@B72], [@B16]--[@B175]\].                                                                                                                                                                B-C
                                                                                                                                                                                                                                                                                                                                                                     
  5   Provide consistent and varied staff education on consequences of poor technique along with clinical reminders of best practice \[[@B35], [@B23], [@B169], [@B160], [@B16], [@B9]--[@B190]\].                                                                                                                                                                   C
                                                                                                                                                                                                                                                                                                                                                                     
  6   Establish regular surveillance of compliance for disinfection of intravascular devices prior to access with reporting of results to each care unit \[[@B1], [@B24], [@B161], [@B181], [@B25]--[@B194]\].                                                                                                                                                       C
                                                                                                                                                                                                                                                                                                                                                                     
  7   Establish a formal process to evaluate new technology and needleless connector designs \[[@B7], [@B93], [@B97], [@B100]\].                                                                                                                                                                                                                                     A
                                                                                                                                                                                                                                                                                                                                                                     
  8   Implement a multimodal quality improvement infection prevention program that applies guidelines and recommendations to all intravascular practices \[[@B30], [@B181], [@B188], [@B64]--[@B195]\].                                                                                                                                                              B

^\*^Grade of recommendation was modified from the NHMRC definitions (NHMRC, 2009) \[[@B206]\]. To achieve a grade of A the research is required to be a high quality randomized control trial (RCT) or a systematic review of high quality RCTs. Laboratory (in vitro) research was classified as level V evidence (DeVries and Berlet, 2010 \[[@B207]\]; The University of Newcastle Australia, 2014 \[[@B208]\]).

A: body of evidence can be trusted to guide practice, systematic review or RCT.

B: body of evidence can be trusted to guide practice in most situations, RCT or high quality observational study.

C: body of evidence provides some support for recommendation but care should be taken in its application, observational studies.

D: Level V evidence or evidence that is weak and recommendation must be applied with caution, expert opinion, animal, or laboratory studies.
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